Robert W. Baird Cuts Astrana Health (NASDAQ:ASTH) Price Target to $50.00

Astrana Health (NASDAQ:ASTH) had its price target trimmed by Robert W. Baird from $86.00 to $50.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

ASTH has been the topic of several other reports. Stifel Nicolaus dropped their price target on Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Truist Financial dropped their price target on Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Finally, Macquarie raised Astrana Health to a “hold” rating in a research report on Monday, December 16th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.83.

Astrana Health Stock Performance

Shares of ASTH opened at $27.19 on Monday. The business’s 50 day moving average is $34.57 and its two-hundred day moving average is $44.16. Astrana Health has a 52-week low of $23.12 and a 52-week high of $63.20. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of 20.92, a PEG ratio of 1.37 and a beta of 1.20. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The business had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Analysts forecast that Astrana Health will post 1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ASTH. State Street Corp bought a new position in Astrana Health during the 3rd quarter worth $91,966,000. Geode Capital Management LLC bought a new position in Astrana Health during the 3rd quarter worth $58,995,000. FMR LLC bought a new position in Astrana Health during the 3rd quarter worth $48,413,000. Loomis Sayles & Co. L P bought a new position in Astrana Health during the 3rd quarter worth $30,251,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Astrana Health during the 3rd quarter worth $25,945,000. 52.77% of the stock is currently owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.